1734.TW
Sinphar Pharmaceutical Co.,Ltd. [1734.TW] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
1734.TW Stock Summary
Top 10 Correlated ETFs
1734.TW
Top 10 Correlated Stocks
1734.TW
In the News
1734.TW Financial details
Company Rating
Buy
Market Cap
6.14B
Income
375.17M
Revenue
2.96B
Book val./share
18.47
Cash/share
6.45
Dividend
1
Dividend %
2.99%
Employees
984
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
23.14
Forward P/E
-
PEG
1.8
P/S
1.89
P/B
1.87
P/C
5.53
P/FCF
172.9
Quick Ratio
1.42
Current Ratio
2.08
Debt / Equity
0.63
LT Debt / Equity
0.44
-
-
EPS (TTM)
2.24
EPS next Y
-
EPS next Q
-
EPS this Y
128.57%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
4.35%
Revenue Q/Q
4.58%
EPS Q/Q
46.67%
-
-
-
-
SMA20
2.78%
SMA50
12.12%
SMA100
12.12%
Inst Own
-
Inst Trans
-
ROA
4%
ROE
8%
ROC
0.05%
Gross Margin
36%
Oper. Margin
7%
Profit Margin
8%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
31.0-41.1
52W High
-12.93%
52W Low
+15.16%
RSI
49
Rel Volume
1.08
Avg Volume
988.27K
Volume
1.07M
Perf Week
-5.43%
Perf Month
6.89%
Perf Quarter
12.97%
Perf Half Y
13.33%
-
-
-
-
Beta
0.673
-
-
Volatility
0.41%, 0.75%
Prev Close
-1.92%
Price
35.7
Change
-2.19%
1734.TW Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 14.28 | 14.24 | 14.51 | 17.03 | 17.67 | |
| Net income per share | -0.88 | -1.03 | -1.22 | 0.98 | 2.24 | |
| Operating cash flow per share | -0.47 | 0.87 | 0.81 | 2.54 | 1.77 | |
| Free cash flow per share | -1.53 | -0.07 | -0.15 | 1.62 | -0.03 | |
| Cash per share | 5.28 | 7.12 | 7.42 | 7.42 | 6.45 | |
| Book value per share | 16.59 | 16.36 | 16.23 | 17.47 | 18.47 | |
| Tangible book value per share | 17.96 | 17.81 | 17.65 | 18.66 | 20.26 | |
| Share holders equity per share | 16.59 | 16.36 | 16.23 | 17.47 | 18.47 | |
| Interest debt per share | 11.69 | 12.45 | 12.87 | 11.57 | 11.8 | |
| Market cap | 3.25B | 5.19B | 4.85B | 5.56B | 5.69B | |
| Enterprise value | 4.35B | 6.11B | 5.79B | 6.24B | 6.56B | |
| P/E ratio | -22 | -30.08 | -23.65 | 33.87 | 15.18 | |
| Price to sales ratio | 1.36 | 2.17 | 1.99 | 1.95 | 1.92 | |
| POCF ratio | -40.94 | 35.46 | 35.76 | 13.07 | 19.21 | |
| PFCF ratio | -12.7 | -456.23 | -187.15 | 20.45 | -1.25K | |
| P/B Ratio | 1.17 | 1.89 | 1.78 | 1.9 | 1.84 | |
| PTB ratio | 1.17 | 1.89 | 1.78 | 1.9 | 1.84 | |
| EV to sales | 1.82 | 2.56 | 2.38 | 2.18 | 2.22 | |
| Enterprise value over EBITDA | 24.95 | 39.34 | 51.58 | 11.55 | 11.23 | |
| EV to operating cash flow | -54.74 | 41.74 | 42.69 | 14.66 | 22.15 | |
| EV to free cash flow | -16.98 | -537.02 | -223.43 | 22.94 | -1.44K | |
| Earnings yield | -0.05 | -0.03 | -0.04 | 0.03 | 0.07 | |
| Free cash flow yield | -0.08 | 0 | -0.01 | 0.05 | 0 | |
| Debt to equity | 0.7 | 0.75 | 0.78 | 0.65 | 0.63 | |
| Debt to assets | 0.33 | 0.34 | 0.34 | 0.31 | 0.31 | |
| Net debt to EBITDA | 6.29 | 5.92 | 8.38 | 1.25 | 1.49 | |
| Current ratio | 1.96 | 1.91 | 1.76 | 1.92 | 2.2 | |
| Interest coverage | -2.7 | -3.88 | -6.34 | 9.83 | 8.49 | |
| Income quality | 0.92 | -1.24 | -0.73 | 1.74 | 0.97 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | |
| Payout ratio | -0.11 | -0.19 | -0.16 | 0.2 | 0.45 | |
| Sales general and administrative to revenue | 0.1 | 0.09 | 0.08 | 0.07 | 0.08 | |
| Research and developement to revenue | 0.22 | 0.19 | 0.21 | 0.1 | 0.04 | |
| Intangibles to total assets | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 | |
| Capex to operating cash flow | 2.22 | -1.08 | -1.19 | -0.36 | -1.02 | |
| Capex to revenue | -0.07 | -0.07 | -0.07 | -0.05 | -0.1 | |
| Capex to depreciation | -0.75 | -0.63 | -0.6 | -0.58 | -1.24 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 18.15 | 19.46 | 21.13 | 19.62 | 30.49 | |
| ROIC | -0.02 | -0.03 | -0.04 | 0.04 | 0.07 | |
| Return on tangible assets | -0.03 | -0.03 | -0.03 | 0.03 | 0.06 | |
| Graham Net | -5.61 | -5.68 | -5.88 | -4.54 | -4.83 | |
| Working capital | 1.11B | 1.21B | 1.17B | 1.33B | 1.44B | |
| Tangible asset value | 3.01B | 2.99B | 2.96B | 3.13B | 3.33B | |
| Net current asset value | -451.71M | -443.46M | -440.4M | -189.89M | -204.6M | |
| Invested capital | 0.7 | 0.75 | 0.78 | 0.65 | 0.63 | |
| Average receivables | 730.63M | 732.35M | 705.48M | 771.7M | 757.44M | |
| Average payables | 196.15M | 202.11M | 197.74M | 262.22M | 307.2M | |
| Average inventory | 527.53M | 624.22M | 689.42M | 717.2M | 788.1M | |
| Days sales outstanding | 122.67 | 100.85 | 112.65 | 101.24 | 89.01 | |
| Days payables outstanding | 52.73 | 46.86 | 47.55 | 66.82 | 56.79 | |
| Days of inventory on hand | 142.36 | 164.4 | 164.78 | 152.38 | 163.65 | |
| Receivables turnover | 2.98 | 3.62 | 3.24 | 3.61 | 4.1 | |
| Payables turnover | 6.92 | 7.79 | 7.68 | 5.46 | 6.43 | |
| Inventory turnover | 2.56 | 2.22 | 2.22 | 2.4 | 2.23 | |
| ROE | -0.05 | -0.06 | -0.08 | 0.06 | 0.12 | |
| Capex per share | -1.05 | -0.94 | -0.96 | -0.91 | -1.79 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 4.55 | 4.6 | 4.34 | 4.27 | 4.46 | |
| Net income per share | -0.12 | 0.48 | 0.65 | 0.45 | 0.65 | |
| Operating cash flow per share | 0.89 | -0.4 | 0.99 | 0.34 | 0.84 | |
| Free cash flow per share | 0.57 | -0.67 | 0.55 | -0.25 | 0.35 | |
| Cash per share | 7.42 | 5.78 | 6.11 | 5.97 | 6.45 | |
| Book value per share | 17.47 | 17.96 | 17.47 | 18.05 | 18.47 | |
| Tangible book value per share | 18.66 | 19.12 | 18.55 | 19.48 | 20.26 | |
| Share holders equity per share | 17.47 | 17.96 | 17.47 | 18.05 | 18.47 | |
| Interest debt per share | 11.46 | 10.49 | 10.37 | 11.65 | 11.65 | |
| Market cap | 5.56B | 5.19B | 6.07B | 5.43B | 5.69B | |
| Enterprise value | 6.24B | 5.98B | 6.79B | 6.38B | 6.56B | |
| P/E ratio | -68.53 | 16.2 | 13.92 | 17.81 | 12.96 | |
| Price to sales ratio | 7.29 | 6.73 | 8.34 | 7.58 | 7.61 | |
| POCF ratio | 37.43 | -77.24 | 36.61 | 95.31 | 40.44 | |
| PFCF ratio | 58.57 | -45.9 | 66.01 | -131.32 | 98.4 | |
| P/B Ratio | 1.9 | 1.72 | 2.07 | 1.79 | 1.84 | |
| PTB ratio | 1.9 | 1.72 | 2.07 | 1.79 | 1.84 | |
| EV to sales | 8.18 | 7.75 | 9.33 | 8.91 | 8.77 | |
| Enterprise value over EBITDA | 91.54 | 37.05 | 63.13 | 48.04 | 35.87 | |
| EV to operating cash flow | 41.98 | -88.96 | 40.92 | 112.02 | 46.62 | |
| EV to free cash flow | 65.69 | -52.87 | 73.78 | -154.34 | 113.44 | |
| Earnings yield | 0 | 0.02 | 0.02 | 0.01 | 0.02 | |
| Free cash flow yield | 0.02 | -0.02 | 0.02 | -0.01 | 0.01 | |
| Debt to equity | 0.65 | 0.58 | 0.59 | 0.64 | 0.63 | |
| Debt to assets | 0.31 | 0.29 | 0.29 | 0.32 | 0.31 | |
| Net debt to EBITDA | 9.92 | 4.88 | 6.65 | 7.17 | 4.76 | |
| Current ratio | 1.92 | 2.19 | 1.96 | 2.08 | 2.2 | |
| Interest coverage | 0.04 | 12.27 | 5.9 | 8.78 | 12.45 | |
| Income quality | -15.7 | -0.72 | 4.38 | 0.89 | 1.28 | |
| Dividend Yield | 0 | 0 | 0 | 0.03 | 0 | |
| Payout ratio | 0 | 0 | 0 | 2.2 | 0 | |
| Sales general and administrative to revenue | 0.07 | 0.07 | 0.07 | 0.08 | 0.09 | |
| Research and developement to revenue | 0.15 | 0.06 | 0.07 | 0.08 | -0.02 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Capex to operating cash flow | -0.36 | 0.68 | -0.45 | -1.73 | -0.59 | |
| Capex to revenue | -0.07 | -0.06 | -0.1 | -0.14 | -0.11 | |
| Capex to depreciation | -0.79 | -0.77 | -1.25 | -1.62 | -1.29 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 6.89 | 13.89 | 15.99 | 13.58 | 16.5 | |
| ROIC | 0 | 0.02 | 0.03 | 0.01 | 0.02 | |
| Return on tangible assets | 0 | 0.01 | 0.02 | 0.01 | 0.02 | |
| Graham Net | -4.54 | -4.25 | -4.94 | -5.47 | -4.83 | |
| Working capital | 1.33B | 1.4B | 1.25B | 1.34B | 1.44B | |
| Tangible asset value | 3.13B | 3.21B | 3.11B | 3.19B | 3.33B | |
| Net current asset value | -189.89M | -111.24M | -246.58M | -314.48M | -204.6M | |
| Invested capital | 0.65 | 0.58 | 0.59 | 0.64 | 0.63 | |
| Average receivables | 772.7M | 794.88M | 757.09M | 736.36M | 739.23M | |
| Average payables | 305.92M | 306.39M | 282.4M | 276.52M | 284.53M | |
| Average inventory | 743.63M | 767.99M | 793.77M | 802.78M | 828.09M | |
| Days sales outstanding | 93.52 | 93.08 | 88.66 | 95.05 | 86.87 | |
| Days payables outstanding | 59.54 | 53.87 | 51.46 | 56.68 | 56.32 | |
| Days of inventory on hand | 135.79 | 148.62 | 147.45 | 166.67 | 162.29 | |
| Receivables turnover | 0.96 | 0.97 | 1.02 | 0.95 | 1.04 | |
| Payables turnover | 1.51 | 1.67 | 1.75 | 1.59 | 1.6 | |
| Inventory turnover | 0.66 | 0.61 | 0.61 | 0.54 | 0.55 | |
| ROE | -0.01 | 0.03 | 0.04 | 0.03 | 0.04 | |
| Capex per share | -0.32 | -0.27 | -0.44 | -0.59 | -0.49 |
1734.TW Frequently Asked Questions
What is Sinphar Pharmaceutical Co.,Ltd. stock symbol ?
Sinphar Pharmaceutical Co.,Ltd. is a TW stock and trading under the symbol 1734.TW
What is Sinphar Pharmaceutical Co.,Ltd. stock quote today ?
Sinphar Pharmaceutical Co.,Ltd. stock price is $35.7 today.
Is Sinphar Pharmaceutical Co.,Ltd. stock public?
Yes, Sinphar Pharmaceutical Co.,Ltd. is a publicly traded company.
Company Profile
- Volume Average 988.27K
- Market Capitalization 6.14B
- Employee 984
- CEO Mr. Zhiwen Li
- Headquarters Yilan City,TW
- IPO Date 2002-08-27
-
Website
https://www.sinphar.com.tw 
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, researches, develops, manufactures, and sells therapeutic drugs, health care foods, and medical beauty products in Taiwan and internationally. It produces anti-cancer pharmaceuticals, such as injections, solid reagents, and hormone reagents; and tablets, soft gel capsules and powder and canned special nutrient products. The company also offers shampoo, body wash, tonic water, lotions, moisturizers, sunscreen lotions, and serums; and pharmaceutical packaging products, such as eye drop bottles, dry canisters, tablet bottles, and various medical grade plastic containers. In addition, it provides plant extracts and functional foods; and OEM services, such as product design, manufacturing, etc. to manufacturers. The company was founded in 1977 and is headquartered in Yilan City, Taiwan.
